Integrative genomic analysis facilitates precision strategies for glioblastoma treatment.

iScience · 2022 · PMC9589211 · PMID 36300002

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As shown in Table S9 , NVP−BEZ235 and dasatinib showed a trend for preferential effect, which was entirely consistent with the prediction results of our bioinformatic analyses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.